July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Long-term outcome of steroid eye drop therapy for diabetic macular edema
Author Affiliations & Notes
  • Sachi Abe
    Yamagara University Sch of Med, Yamagata, Yamagata, Japan
  • Koichi Nishitsuka
    Yamagara University Sch of Med, Yamagata, Yamagata, Japan
  • Hidetoshi Yamashita
    Yamagara University Sch of Med, Yamagata, Yamagata, Japan
  • Footnotes
    Commercial Relationships   Sachi Abe, SENJU PHARMACEUTICAL CO., LTD. (P); Koichi Nishitsuka, None; Hidetoshi Yamashita, SENJU PHARMACEUTICAL CO., LTD. (P)
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 4827. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sachi Abe, Koichi Nishitsuka, Hidetoshi Yamashita; Long-term outcome of steroid eye drop therapy for diabetic macular edema. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4827.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Steroid therapy for diabetic macular edema (DME) has been established. We reported the efficacy of steroid eye drops(difluperdonate ophthalmic emulsion, ) for the treatment of DME. Eye drops are most non-invasive device for DME therapy. To determine the long-term outcomes of patients treated with steroid eye drops.

Methods : A retrospective, non-comparative, log-term observational study. Changes and outcomes of visual acuity and central retinal thickness were assessed in patients who started drug therapy with steroid eye drops.

Results : This study included 98 eyes of 66 patients who had started treatment with the eye drops and had then been followed up for 12 months or longer. Before treatment, the mean logarithm minimum angle of resolution visual acuity(BCVA) was 0.397 ± 0.29, and the mean central retinal thickness(CRT) was 458.9 ± 122.1 mm. There were 49 eyes (50%) that had been treated with the eye drops alone for 12 months or longer. The other 49 eyes were additionally treated with topical steroid therapy, anti-vascular endothelial growth factor therapy, pars plana vitrectomy, etc. During follow up, the BCVA changed as follows: 0.367 before treatment, 0.317 at 1 month of treatment (p = 0.195), 0.300 at 2 months (p = 0.119), 0.265 at 3 months (p = 0.001), 0.251 at 6 months (p = 0.005), and 0.251 at 12 months (p = 0.007). The CRT decreases were as follows: 431.8, 355.4 (p = 0.000), 335.8 (p = 0.000), 348.0 (p = 0.000), 361.9 (p = 0.012), and 330.8 (p = 0.000) mm.

Conclusions : Approximately half of the patients with DME who started steroid eye drop therapy were treated with the eye drops alone for 12 months or longer and achieved improvement in visual acuity and retinal thickness non-invasively.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×